Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161452 | 0.83 | TDP1 (0.47) | CA12CA2CA14CA1CA7 | |
| SCHEMBL30141310 | 0.83 | CA2 (0.41) | CA12CA2CA14CA1CA7 | |
| SCHEMBL756075 | 0.78 | CA12 (0.52) | CA12CA2CA14CA1CA7 | |
| SCHEMBL12972389 | 0.78 | TDP1 (0.42) | CA12CA2CA14CA1CA7 | |
| SCHEMBL1950351 | 0.77 | TDP1 (0.47) | CA12CA2CA14CA1CA7 | |
| SCHEMBL3677388 | 0.77 | TDP1 (0.47) | CA12CA2CA14CA1CA7 | |
| SCHEMBL29098389 | 0.77 | CA12 (0.50) | CA12CA2CA14CA1CA7 | |
| SCHEMBL3187413 | 0.77 | TDP1 (0.50) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23332545 | 0.76 | TDP1 (0.46) | CA12CA2CA14CA1TDP1 | |
| SCHEMBL3984277 | 0.76 | TDP1 (0.46) | CA12CA2CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2017075694-A1 | ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR | SIMON FRASER UNIVERSITY (CA) | 2017-05-11 | — | — | WO | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | CA12 4127/4885CA2 3864/4885CA14 4147/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | CA12 4127/4885CA2 3864/4885CA14 4147/4885 |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | CA12 4488/4885CA2 4208/4885CA14 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.